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ABSTRACT
Introduction. The rates of allergic rhinitis, allergic asthma, and atopic eczema range from 6% to 16% globally.
Second-generation antihistamines have been shown to be safe and effective for the treatment of symptoms of allergic
disease. This study investigated the efﬁcacy and safety of desloratadine, a nonsedating second-generation antihista-
mine, in the treatment of common allergy symptoms.
Methods. In this open-label, uncontrolled, non-randomized, observational study, subjects (N = 973) with allergy
symptoms were given desloratadine 5 mg daily for 3 weeks. Nasal, ocular, and dermal symptom severity was rated as
asymptomatic, mild, moderate, or severe; changes in the percentage of subjects in each severity category were
assessed. Overall efﬁcacy and tolerability of desloratadine treatment were evaluated separately by physicians and
subjects.
Results. Allergic rhinitis was the most frequent diagnosis, occurring in 59.0% of subjects. Approximately 40% of
subjects had received previous treatment with other antihistamines, systemic/topical glucocorticosteroids, or beta-
sympathicomimetics. Slightly more than half of subjects received concomitant medication during the study; 263
(53.0%) of those used intranasal steroids. A signiﬁcant reduction in severity scores was observed in all symptom
subgroups (P < 0.001). Desloratadine efﬁcacy was judged to be excellent or good by 90.2% of physicians and 88.6%
of subjects; 82.5% of investigators and 80.9% of subjects considered it more effective than previous therapy. The
tolerability of desloratadine was rated excellent or good by 97.0% of both groups. Thirty-one subjects (3.2%)
experienced adverse events.
Conclusions. In an open-label, uncontrolled, non-randomized, observational study allergy symptoms improved
signiﬁcantly in subjects treated with desloratadine.
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he prevalence of allergic disease has
increased dramatically worldwide [1]. A sur-
vey conducted in 2007 by the World Allergy
Organization revealed that the prevalence of aller-
gic rhinitis was greater than 16% in most of the 37
countries reporting and reached as high as 40% in
the Ukraine. Rates of allergic asthma ranged from
6% to 15% in 35 countries surveyed, which was
also the range of prevalence rates of atopic eczema
reported by 30 countries [2].
Allergy symptoms—nasal congestion; nasal
itching; rhinorrhea; sneezing; burning, watery
eyes; itching skin and wheals—can be debilitating
and often impair sleep, work/school productivity,
learning, and concentration, signiﬁcantly reducing
quality of life [3–7]. The allergic inﬂammatory
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events in which histamine plays a crucial role.
Many of the inﬂammatory and immunomodula-
tory effects of histamine are mediated through the
H1-receptor [8,9]. Therefore, H1-receptor antago-
nists are often recommended ﬁrst-line treatments
for conditions involving activation of allergic
inﬂammation [10–13].
Second-generation oral antihistamines, such as
desloratadine, fexofenadine, and levocetirizine,
rapidly reduce allergic rhinitis–related nasal symp-
toms (rhinorrhea, sneezing/itching) and ocular
symptoms (tearing, itching, redness) as well as der-
matologic symptoms of chronic urticaria (wheals,
itching) with little or no somnolence [12]. These
agents may also inhibit the actions of other mast
cell and basophil mediators that cause nasal
obstruction and inﬂammation of nasal mucosa
[14].
Desloratadine is a potent, nonsedating
H1-receptor antagonist with antiallergic and anti-
inﬂammatory properties. In vitro studies have
shown that desloratadine inhibits chemical media-
tors involved in both the early- and late-phase
allergic responses [12]. Desloratadine has also
been found to improve nasal airﬂow in patients
with allergic rhinitis [15]. The proven ability of
desloratadine to prevent the release of cytokines,
chemokines, and cellular adhesion molecules asso-
ciated with the late-phase response may contribute
to its decongestant properties [12,16–19].
The objectives of this observational study
were to evaluate the efﬁcacy of desloratadine in
improving nasal, ocular, and dermal allergy
symptoms; to assess the drug’s adverse event
proﬁle; and to determine investigator and subject
satisfaction with desloratadine treatment in a
real-life environment.
Methods
This multicenter, observational study was con-
ducted by 85 dermatology specialists and in three
hospital allergy units in Austria in subjects aged
12 years or older who were currently experiencing
allergy symptoms related to allergic rhinitis (with
or without comorbidities such as conjunctivitis,
bronchial hyperreactivity, or asthma); sinusitis, lar-
yngitis, or polyposis; chronic idiopathic urticaria;
skin or food allergies; or bronchial hyperreactivity
or asthma. Written informed consent was obtained
from all subjects. According to Austrian law on
medicinal products, no ofﬁcial institutional review
by the Medical University of Graz was required
because, in this study, desloratadine was prescribed
according to the indications (allergic rhinitis and
chronic idiopathic urticaria) in the label approved
at the time. Neither the investigators nor the sub-
jects were paid for their participation in this study.
The study drug was supplied free of charge.
Study candidates were excluded if they were
pregnant or breastfeeding or were receiving
current or continuing treatment with other sys-
temic antihistamines.
The participants received desloratadine 5 mg
once daily for 3 weeks. Subjects could also be pre-
scribed concomitant medications, e.g., corticoster-
oids for nasal congestion, if an investigator felt it
was warranted.
Allergy symptoms were assessed at the begin-
ning and end of treatment with desloratadine.
Subjects completed daily diaries, categorizing
their symptoms into 3 subgroups: nasal (conges-
tion, rhinorrhea, sneezing/itching), ocular (tear-
ing, burning/itching, redness), and dermal
(itching, wheals, dryness) and scoring them ac-
cording to 4 levels of severity: 0 = asymptomatic,
1 = mild, 2 = moderate, or 3 = severe. Subjects
were instructed on diary use, and the importance
of completing them was stressed. Change between
baseline and study endpoint in percentage of sub-
jects in each category of symptom severity were
analyzed using the McNemar test and Wilco-
xon signed-rank test. Percentages were derived
without accounting for missing values. In addition,
the overall efﬁcacy of desloratadine therapy was
assessed separately by investigators and subjects at
study end using 4 descriptors—excellent, good,
moderate, or inadequate. Further, investigators
who had previously administered allergy treatment
to the study subjects, and the subjects who had
received such treatment, judged whether deslora-
tadine “was better than prior therapy.”
Tolerability of desloratadine therapy was
assessed separately by investigators and subjects at
study end using the same 4 descriptors as used for
efﬁcacy analysis. Subjects were asked to report all
potential adverse effects, including dry mouth,
somnolence, headache, or gastrointestinal upset.
In addition, subjects described the onset of any
new illnesses or exacerbations of existing illnesses
after beginning desloratadine treatment.
Results
Subjects
A total of 1,015 subjects were enrolled. Data
were available for 973 subjects who received
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to treat more than one type of allergy. Forty-two
subjects did not complete the study; their data
were not included in the analysis. No subject dis-
continued due to lack of response.
The mean age of the study population was
37.5 years, and 58% were women. Allergic rhinitis
was identiﬁed as the sole type of allergy in 59.2%
(N = 574) of subjects and in conjunction with
bronchial asthma in another 10.3% (N = 100).
Nearly 40% of subjects had received previous
allergy treatment with sedating and other non-
sedating antihistamines, glucocorticosteroids,
or beta-sympathicomimetics (Table 1) for a mean
duration of 27.2 days (range 2 to 202 days). A total
of 496 subjects (51.0%) received concomitant
medications during the study; 263 (53.0%) of
those used intranasal steroids. The proportion
of comedicated subjects receiving any other class
of medication, including topical antihistamines,
was <10%.
Efﬁcacy
The data showed that nasal, ocular, and dermal
symptoms all improved signiﬁcantly following
desloratadine treatment (P < 0.001).
Nasal Symptoms
The percentage of subjects with no or only mild
nasal symptoms increased from 42.9% at base-
line to 95.2% after desloratadine treatment for
sneezing/itching; from 40.5% to 94.4% for rhin-
orrhea; and from 33.7% to 90.7% for nasal con-
gestion (Figure 1). The proportion with moderate
or severe nasal symptoms decreased from 57.2% at
baseline to 4.8% at endpoint in subjects with
sneezing/itching; from 59.5% to 5.6% in those
with rhinorrhea; and from 66.2% to 9.2% in those
with nasal congestion.
Ocular Symptoms
From baseline to endpoint, the proportion of
subjects with no or only mild ocular symptoms
increased from 70.4% to 97.7% for redness; from
65.0% to 96.2% for tearing; and from 59.0% to
95.9% for burning/itching (Figure 2). The pro-
portion of subjects with moderate-to-severe symp-
toms decreased from 29.6% to 2.3% for redness,
from 35.0% to 3.8% for tearing, and from 41.0%
to 4.2% for burning/itching.
Dermal Symptoms
The proportion of subjects with no or mild dermal
symptoms increased from 72.8% at baseline to
94.0% after desloratadine therapy for wheals; from
83.6% to 91.6% for dryness, and from 62.2% to
90.5% for itching (Figure 3). The percentages of
subjects experiencing moderate and severe dermal
symptoms decreased from 27.2% to 6.0% for
wheals, from 16.5% to 8.4% for dryness, and from
37.9% to 9.5%% for itching.
Investigator/Subject Evaluations
Desloratadine efﬁcacy was determined to be excel-
lent or good by 90.2% of physicians and 88.5% of
subjects at the end of therapy (Figure 4). More-
over, approximately 97% of participants in both
groups rated the tolerability of desloratadine with
these top 2 descriptors. Investigators (82.5%) and
subjects (80.9%) described treatment with deslo-
ratadine as being better than previous allergy
therapy. Of all subjects remaining on any medica-
tion at endpoint, 88.0% elected to continue treat-
ment with desloratadine.
Safety
Adverse events were reported by 3.2% of subjects
(N = 31). Fatigue was the most common adverse
event (0.8%), followed by dry mouth, gastritis, and
headache (0.3% each). No subject discontinued
due to adverse effects.
Discussion
The ﬁndings of improved allergy symptoms
conﬁrm the results of previous studies indicating
that desloratadine is an effective and well-tolerated
treatment for the common signs and symptoms
Table 1 Concomitant medications
Medication (multiple responses
possible)
Subjects, N (% of
total population)
Antiallergic agent (topical) 27 (2.8)
Antibiotics 3 (0.3)
Antidepressant 4 (0.4)
Antihistamine (topical) 38 (3.9)
Beta-sympathicomimetic 39 (4.0)
Glucocorticoid
Dermal cream/lotion 18 (1.9)
Bronchial 27 (2.8)
Combined 10 (1.0)
Intranasal spray 263 (27.0)
Systemic 9 (0.9)
Hyposensitization 11 (1.1)
Leukotriene inhibitor 9 (0.9)
Local vasoconstrictor 8 (0.8)
Other 80 (8.2)
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rhinitis, including nasal congestion [20–25], and
chronic urticaria [26–28]. Desloratadine treatment
signiﬁcantly reduced total nasal and non-nasal
symptom scores from baseline and decreased pru-
ritus scores and number and size of wheals associ-
ated with moderate-to-severe chronic idiopathic
urticaria.
Figure 1 Baseline-to-endpoint
changes in severity of nasal symp-
toms of sneezing/itching (A), rhinor-
rhea (B), and congestion (C) after
3 weeks of desloratadine treatment.
Severity was rated as asymptomatic,
mild, moderate, or severe.
Figure 2 Baseline-to-endpoint
changes in severity of ocular redness
(A), tearing (B), and burning/itching
(C) after 3 weeks of desloratadine
treatment. Severity was rated as
asymptomatic, mild, moderate, or
severe.
Figure 3 Baseline-to-endpoint
changes in severity of wheals (A),
dryness (B), and itching (C) after
3 weeks of desloratadine treatment.
Severity was rated as asymptomatic,
mild, moderate, or severe.
20 Aberer
Arch Drug Info 2009;2:17–22Limitations
In this study, we used a single agent in an open-
label, non–placebo-controlled design. In addition,
51.0% of subjects were receiving concomitant
medications, including 263 (27.0%) subjects who
were using intranasal steroids. However, this
design in a patient population normally seen in
clinical practice more closely approximates a phy-
sician’s everyday experience. Moreover, we cannot
infer that the improvements observed would have
lasted beyond 3 weeks of the study. It is also pos-
sible that, over the course of the study to endpoint,
subjects’ symptoms may have abated independent
of desloratadine treatment.
Conclusion
In this open-label, uncontrolled, observational
study, treatment with desloratadine resulted in a
signiﬁcant reduction in severity scores in all
allergy symptom subgroups. Both investigators
and subjects rated desloratadine efﬁcacy as excel-
lent or good.
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